BBLG RSI Chart
Last 7 days
-2.1%
Last 30 days
6.2%
Last 90 days
-51.5%
Trailing 12 Months
-95.2%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 13, 2023 | walsh deina h | bought | 5,120 | 0.64 | 8,000 | chief financial officer |
Sep 11, 2023 | frelick jeff | bought | 6,530 | 0.6874 | 9,500 | chief executive officer |
Sep 06, 2023 | walsh deina h | bought | 4,967 | 0.709571 | 7,000 | chief financial officer |
Aug 31, 2023 | frelick jeff | bought | 5,019 | 0.6605 | 7,600 | chief executive officer |
Mar 13, 2023 | hankey don | sold | - | - | -500,137 | chairman of the board |
Oct 15, 2021 | hankey don | acquired | 2,495,240 | 5.24 | 476,190 | chairman of the board |
Oct 15, 2021 | hankey don | gifted | - | - | -1,004,310 | chairman of the board |
Oct 15, 2021 | hankey don | sold | - | - | -9,361,700 | chairman of the board |
Oct 15, 2021 | hankey don | acquired | 14,821,900 | 2.5 | 5,928,770 | chairman of the board |
Jan 02, 2020 | hankey don | bought | 195,000 | 1.00 | 195,000 | chairman of the board |
Which funds bought or sold BBLG recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 568,236 | 568,236 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 246 | 3,515 | 9,052 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | new | - | 78,810 | 78,810 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 414 | 414 | -% |
May 13, 2024 | UBS Group AG | new | - | 1,278 | 1,278 | -% |
May 13, 2024 | CLEAR STREET LLC | new | - | 2,000 | 2,000 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | unchanged | - | -10.00 | 9.00 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -8,000 | - | -% |
Unveiling Bone Biologics Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bone Biologics Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Bone Biologics Corp News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | 2.7% | 3,840 | 3,738 | 4,976 | 7,623 | 6,784 | 8,495 | 5,201 | 5,659 | 6,094 | 6,675 | 4,474 | 2,273 | 71.00 | 51.00 | 31.00 | 249 | 266 | 814 | 1,041 | 2,350 | 378 |
Current Assets | 2.7% | 3,840 | 3,738 | - | - | - | 8,495 | - | - | - | - | - | - | - | - | 31.00 | 249 | 266 | 814 | 1,041 | 2,350 | 378 |
Cash Equivalents | -100.0% | - | 3,000 | 4,500 | 7,008 | 6,188 | 7,538 | 5,059 | 5,455 | 5,815 | 6,675 | 3.00 | 4.00 | 71.00 | 2.00 | 24.00 | 202 | 176 | 726 | 955 | 2,294 | 305 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26* | 50* | 74* | 98* |
Liabilities | -80.2% | 165 | 831 | 1,183 | 1,930 | 4,011 | 2,548 | 799 | 4,394 | 7,989 | 11,583 | 15,178 | 14,620 | 14,195 | 12,471 | 11,898 | - | - | - | 9,639 | 9,525 | 9,834 |
Current Liabilities | -80.2% | 165 | 831 | 1,183 | 1,930 | 4,011 | 2,548 | - | - | - | 100 | - | - | - | 12,471 | 578 | 11,631 | 11,122 | 10,786 | 9,639 | 525 | 1,271 |
Shareholder's Equity | 26.4% | 3,675 | 2,906 | 3,793 | 5,693 | 2,772 | 5,947 | 4,402 | 5,588 | 6,039 | 6,575 | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings | -1.1% | -81,774 | -80,900 | -79,400 | -77,400 | -75,700 | -71,960 | -72,900 | -71,634 | -71,165 | -70,475 | -70,297 | -69,788 | -69,296 | -67,637 | -67,040 | -66,509 | -65,947 | -65,022 | -63,615 | -62,144 | -61,902 |
Additional Paid-In Capital | 1.9% | 85,449 | 83,815 | 83,152 | 83,129 | 78,426 | 77,907 | 77,245 | 77,212 | 77,194 | 77,051 | 55,160 | 55,142 | 55,142 | 55,142 | 55,142 | 55,096 | 55,062 | 55,022 | 54,991 | 54,962 | 50,620 |
Shares Outstanding | 90.3% | 1,016 | 534 | 392 | 392 | 2,088 | 64.00 | 43.00 | 43.00 | 43.00 | 43.00 | 12.00 | 12.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 4,163 | - | - | - | 4,403 | - | - | - | 1,260 | - | - | - | - | 520 | - | - | - | 6,005 |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 38.1% | -1,300 | -2,100 | -2,500 | -3,700 | -1,300 | -1,950 | -395 | -360 | -860 | -186 | -277 | -635 | -127 | -125 | -72.23 | -79.13 | -149 | -297 | -474 | -1,550 | -928 |
Share Based Compensation | -25.9% | 53.00 | 71.00 | 20.00 | 17.00 | 45.00 | 63.00 | 33.00 | 19.00 | 153 | - | - | - | - | - | - | - | - | 3.00 | 7.00 | 14.00 | 26.00 |
Cashflow From Financing | 154.1% | 1,504 | 592 | - | 4,452 | - | - | - | - | - | 6,859 | 277 | 569 | 199 | 123 | 75.00 | 77.00 | 128 | 120 | 500 | 1,000 | 700 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenues | ||
Operating expenses | ||
Research and development | 245,625 | 2,590,645 |
General and administrative | 657,911 | 556,892 |
Total operating expenses | 903,536 | 3,147,537 |
Loss from operations | (903,536) | (3,147,537) |
Other income (expenses) | ||
Change in fair value of warrant liability | 37,311 | (562,918) |
Interest income | 255 | 556 |
Total other income (expenses) | 37,566 | (562,362) |
Net loss | $ (865,970) | $ (3,709,899) |
Weighted average shares outstanding - basic | 660,928 | 67,211 |
Weighted average shares outstanding - diluted | 660,928 | 67,211 |
Loss per share - basic | $ (1.31) | $ (55.20) |
Loss per share - diluted | $ (1.31) | $ (55.20) |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets | ||
Cash | $ 3,227,634 | $ 3,026,569 |
Advances on research and development contract services | 328,844 | 328,844 |
Prepaid insurance | 273,096 | 372,350 |
Prepaid expenses | 10,000 | 10,000 |
Total current assets | 3,839,574 | 3,737,763 |
Total assets | 3,839,574 | 3,737,763 |
Current Liabilities | ||
Accounts payable and accrued expenses | 146,186 | 360,662 |
Accrued legal settlement | 414,989 | |
Warrant liability | 18,440 | 55,751 |
Total current liabilities | 164,626 | 831,402 |
Total liabilities | 164,626 | 831,402 |
Commitments and Contingencies | ||
Stockholders’ Equity | ||
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,016,489 and 534,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 1,016 | 534 |
Additional paid-in capital | 85,448,860 | 83,814,785 |
Accumulated deficit | (81,774,928) | (80,908,958) |
Total stockholders’ equity | 3,674,948 | 2,906,361 |
Total liabilities and stockholders’ equity | $ 3,839,574 | $ 3,737,763 |